Tirzepatide costs between $299 and $1,086 per month depending on the dose, delivery format, and whether you have insurance coverage. The brand names are Zepbound (for weight loss) and Mounjaro (for type 2 diabetes), both made by Eli Lilly. Your actual out-of-pocket cost varies widely based on how you access the medication.
Self-Pay Pricing Through Eli Lilly
Eli Lilly sells Zepbound directly to patients through its LillyDirect program, bypassing traditional pharmacy markup. The pricing depends on both your dose and the format you choose.
For single-dose vials (the most affordable option), monthly costs through the Zepbound Self Pay Journey Program break down like this:
- 2.5 mg (starting dose): $299 per month
- 5 mg: $399 per month
- 7.5 mg through 15 mg: $449 per month
The KwikPen (a pre-filled injection pen) costs more. Direct-to-patient pricing for the KwikPen runs $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg, and $699 for the 10 mg, 12.5 mg, and 15 mg doses. Most people start at 2.5 mg and gradually increase over several months, so you’ll likely pay the lower prices for the first two to three months before moving to a higher dose.
Cost With Commercial Insurance
The official list price of Zepbound ranges from $499 to $1,086.37 per fill, but that number rarely reflects what insured patients actually pay. If your commercial insurance plan covers Zepbound, your copay will depend on your specific plan’s formulary and benefit structure.
If your commercial insurance does not cover Zepbound, Eli Lilly offers a savings program that brings the cost down to $499 per month for a one-month supply. This program runs through December 31, 2026. It applies specifically to patients who have commercial drug insurance that excludes Zepbound, not to patients on government insurance programs like Medicare or Medicaid.
Many insurers require prior authorization before they’ll cover tirzepatide. This typically means your doctor needs to document that you meet certain clinical criteria, often related to BMI, weight-related health conditions, or previous weight loss attempts. The specific requirements vary by plan, and some commercial insurers still don’t cover weight loss medications at all.
Medicare and Government Insurance
Medicare Part D has historically not covered medications prescribed purely for weight loss. That’s changing, but slowly. Starting July 1, 2026, a new CMS program called the Medicare GLP-1 Bridge will give eligible Medicare Part D beneficiaries access to Zepbound for weight reduction through December 31, 2027. This is a temporary demonstration program, not permanent coverage.
There’s an important distinction here. If your doctor prescribes Zepbound for a condition that Medicare already covers, like moderate to severe obstructive sleep apnea in adults with obesity, that prescription goes through your Part D plan’s normal coverage process, not the Bridge program. The Bridge is specifically for weight loss use that wouldn’t otherwise be covered.
Medicaid coverage varies by state, and most state Medicaid programs have been slow to add tirzepatide for weight management to their formularies.
Compounded Tirzepatide
Compounding pharmacies produce custom versions of tirzepatide, typically costing $250 to $500 per month. The price depends on the dosage, whether it comes in vials or pre-filled syringes, and whether extra ingredients like vitamin B12 are added. Some compounding pharmacies offer prices at the lower end of that range, around $250 to $400 monthly.
Compounded tirzepatide is not FDA-approved in the same way that Zepbound and Mounjaro are. The FDA has gone back and forth on the availability of compounded versions, and the regulatory landscape continues to shift. If you’re considering this route, look for pharmacies that hold third-party accreditation and can verify the purity and potency of their products.
How Costs Add Up Over Time
Tirzepatide is not a short-term medication for most people. Clinical trials involved treatment periods of over a year, and weight regain after stopping is common with all medications in this class. That makes the long-term cost a real consideration.
At the most affordable self-pay price ($299 per month for the starting dose), you’d spend about $3,600 in the first year. But because most people titrate up to higher doses, a more realistic annual estimate using the vial pricing is $4,800 to $5,400 once you reach a maintenance dose of 7.5 mg or above. With KwikPens at the higher doses, that figure climbs to around $8,400 per year.
If you’re comparing options, the key variables are your insurance status, which dose you ultimately need, and whether you’re comfortable with vials (which require drawing up the dose yourself) versus the convenience of a pre-filled pen. The vials offer significant savings at higher doses, cutting the monthly cost by $250 compared to the KwikPen at 10 mg and above.